# Secukinumab

## Cosentyx 150mg prefilled pen

| TAH Drug Code      | [ICOSE](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ICOSE)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | 1. **Plaque Psoriasis** Indicated for the treatment of patients aged 6 years and older with moderate to severe plaque psoriasis who are appropriate candidates for systemic therapy. 2. **Psoriatic Arthritis** Indicated for the treatment of adults with active psoriatic arthritis. COSENTYX can be used alone or in combination with methotrexate. 3. **Axial Spondyloarthritis (axSpA)** - **Ankylosing Spondylitis (AS)** Indicated for the treatment of adult patients with active ankylosing spondylitis. - **Non-radiographic Axial Spondyloarthritis (nr-axSpA)** Indicated for the treatment of adult patients with severe active non-radiographic axial spondyloarthritis who meet all of the following conditions: (1) Inadequate response to or inability to tolerate nonsteroidal anti-inflammatory drugs (NSAIDs). (2) Elevated C-reactive protein (CRP) levels. (3) MRI evidence of inflammatory changes. (4) HLA-B27 positive. 4. **Juvenile Idiopathic Arthritis (JIA)** - **Enthesitis-Related Arthritis (ERA)** Indicated for the treatment of children aged 6 years and older with active enthesitis-related arthritis who have had an inadequate response to or are intolerant to standard treatments. - **Juvenile Psoriatic Arthritis (JPsA)** Indicated for the treatment of children aged 6 years and older with active juvenile psoriatic arthritis who have had an inadequate response to or are intolerant to standard treatments. 5. **Hidradenitis Suppurativa (HS)** Indicated for the treatment of adults with moderate to severe hidradenitis suppurativa (also known as acne inversa) who have had an inadequate response to traditional systemic therapies. |
| Dosing             | SC, plaque psoriasis 300 mg weeks 0, 1, 2, 3, and 4, followed by every 4 weeks.( some patients may only need 150 mg) Psoriatic arthritis, ankylosing spondylitis, Non-radiographic axial spondyloarthritis, 150 mg weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Contraindications  | Hypersensitivity to secukinumab or any component of the product.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Adverse Effects    | [Common] Diarrhea (2.6% to 4.1% ), Nasopharyngitis (Ankylosing spondylitis, 2% or more ; plaque psoriasis, 11.4% to 12.3% ; psoriatic arthritis, 2% or more ), Upper respiratory infection (Ankylosing spondylitis, 2% or more ; plaque psoriasis, 2.5% to 3.2% ; psoriatic arthritis, 2% or more ) [Serious] Crohn's disease (Ankylosing spondylitis, 0.87% ), Crohn's disease, Exacerbation (Plaque psoriasis, 0.09% ), Inflammatory bowel disease, Ulcerative colitis (Ankylosing spondylitis, 0.5%; plaque psoriasis, 0.06% ), Ulcerative colitis, Exacerbation (Plaque psoriasis, 0.06% ), Anaphylaxis, Infectious disease (Ankylosing spondylitis, 31% ; plaque psoriasis (up to 12 weeks), 28.7%; plaque psoriasis (up to 52 weeks), 47.5% ; psoriatic arthritis, 29% )                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| More Info          | [UpToDate](https://www.uptodate.com/contents/secukinumab-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

